Abu Dhabi-based sovereign investor, Mubadala Investment Company has stepped into a partnership deal with the leading artificial intelligence (AI) and cloud computing company, G42 to establish a world-class biopharmaceutical manufacturing campus (Biopharma Campus) in the UAE capital.
The Biopharma Campus is expected to tap into the global state-of-the-art vaccine and therapeutic products to strengthen regional supply chains and support the UAE’s diversification and economic growth agenda.
The new facility will invest in and establish multiple biopharma initiatives, strengthening the expertise of Mubadala’s advanced manufacturing companies as well as G42’s leading capabilities in AI and cloud computing.
The agreement echoes the ambition of Mubadala in creating sustainable healthcare and life science ecosystem within Abu Dhabi, further advancing the UAE’s socio-economic growth.
Global supply shortages and the limited amount of advanced manufacturing activity within the region has resulted in biopharmaceuticals becoming a high-growth market and a priority investment area for Mubadala within the life sciences sector.
Musabbeh Al Kaabi CEO – UAE Investments Mubadala
“Through the establishment of this campus in partnership with G42 and our group companies, we are investing in innovation and reinforcing Abu Dhabi’s rapidly developing life sciences ecosystem. Bringing cutting-edge manufacturing technologies to the UAE will not only strengthen our nation’s biopharma supply chain and pandemic response but provide opportunities for local talent development and long-term, sustainable economic growth.”
For his part, Mr. Peng Xiao, Group CEO, G42, stated that “Over the years, AI and cloud computing technologies have come of age. From their humble origins in the tech sector a decade ago, today these technologies are leveraged across a wide array of industries that value speed, scalability, innovation and resilience. There is a massive opportunity for pharma and healthcare companies to leverage AI and cloud technologies to improve their processes and we at G42 are very pleased to be partnering with Mubadala to build on the respective strengths and further accelerate the development of the UAE’s life sciences ecosystem.”
The Biopharma Campus will focus on end-to-end manufacturing of state-of-the-art biologics and host anchor partnerships with Contract Manufacturing and Development Organisations (CDMOs). The CDMO model will let manufacturers to work with multiple innovators, reducing product risk and enabling economies of scale.
